Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Combinations in Second-line Advanced NSCLC
NCT05529355Phase 2Unknown
- Sponsor
- Anhui Chest Hospital
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
A Phase 2 trial of envafolimab in non-small cell lung cancer (NSCLC), sponsored by Anhui Chest Hospital. Status: unknown.
02
Drugs
envafolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05529355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05529355.